NasdaqGS:TIGR
NasdaqGS:TIGRCapital Markets

Assessing UP Fintech Holding (TIGR) Valuation As Bullish Options Activity Builds Before Earnings

The options market has turned unusually active around UP Fintech Holding (TIGR), as traders pile into call contracts and implied volatility climbs ahead of the company’s expected March 18 earnings release. See our latest analysis for UP Fintech Holding. That options activity comes after a mixed stretch for the stock, with a 1-day share price return of 1.37% at US$8.87 contrasting with a 90-day share price decline of 16.16%, while the 1-year total shareholder return of 33.99% and 3-year total...
NYSE:LAD
NYSE:LADSpecialty Retail

Is Lithia Motors (LAD) Pricing Misalignments Creating An Opportunity After Recent Share Pullback

If you are looking at Lithia Motors and wondering whether the recent share price gives you a fair entry, this article walks through what the current market price might be implying about value. The stock last closed at US$322.60, with returns of a 2.8% decline over 7 days, 6.3% decline over 30 days, 2.9% decline year to date and 8.7% decline over 1 year, set against a 30.8% gain over 3 years and 0.9% decline over 5 years. Recent coverage of Lithia Motors has focused on its position in the US...
NYSE:DTE
NYSE:DTEIntegrated Utilities

Is It Time To Reassess DTE Energy (DTE) After Steady Multi‑Year Share Gains?

If you are wondering whether DTE Energy is fairly priced or offering value right now, it helps to start by looking at how the market has treated the stock over different time frames. DTE Energy shares last closed at US$135.53, with returns of 0.0% over the past 7 days, 5.0% over 30 days, 4.0% year to date, 15.1% over 1 year, 31.6% over 3 years, and 57.1% over 5 years. Recent news flow around DTE Energy has focused on its role as a regulated utility and its ongoing capital investment plans...
NYSE:ELAN
NYSE:ELANPharmaceuticals

Elanco Approvals And Clinic Gains Shape Updated Valuation Outlook

Elanco Animal Health (NYSE:ELAN) has secured USDA approval for Befrena, a new product in its portfolio. The company has also received conditional FDA approval for Credelio Quattro, expanding its parasiticide offerings. Elanco is gaining traction in corporate veterinary channels, deepening its access to high-volume clinic groups. The company reports an ability to raise prices on core products with limited pushback from customers. Elanco Animal Health focuses on medicines and solutions for...
NasdaqGS:UBSI
NasdaqGS:UBSIBanks

United Bankshares Record 2025 Earnings Highlight Scale And Capital Return

United Bankshares (NasdaqGS:UBSI) reported record earnings for 2025, supported by its acquisition of Piedmont Bancorp. The company completed the integration of Piedmont Bancorp, adding to its banking footprint and customer base. United Bankshares also finished a substantial share repurchase program, signaling a focus on returning capital to shareholders. United Bankshares operates as a regional banking group, providing lending, deposit, and related financial services to consumers and...
NasdaqGS:PAYX
NasdaqGS:PAYXProfessional Services

Paychex Adds Ex Cintas CFO As Board Weighs Value And Momentum

Paychex (NasdaqGS:PAYX) has appointed J. Michael Hansen, former Cintas CFO, to its Board of Directors as an independent director. The move expands the Paychex board and brings additional financial and leadership experience from a veteran executive in related industries. For investors watching Paychex at a current share price of $106.19, the board expansion arrives after a 26.0% decline over the past year and a 7.0% decline over the past 30 days. Over longer periods, the stock shows a 36.0%...
NYSE:BAC
NYSE:BACBanks

Bank Of America Weighs 10% Cards And Storm Hit To Growth

Bank of America is weighing new credit card products with interest rates around 10% as policymakers, including President Trump, discuss potential caps on card rates. The bank is also issuing new guidance on the economic impact of Winter Storm Fern, flagging a short term hit to US GDP with an expected recovery later in the year. For investors watching NYSE:BAC, the news ties directly into how one of the largest US banks is responding to political and regulatory pressure on consumer credit...
NYSE:ARE
NYSE:AREHealth Care REITs

Is Alexandria Real Estate Equities (ARE) Pricing Reflecting Recent Share Price Swings?

If you are wondering whether Alexandria Real Estate Equities is attractively priced right now, starting with a clear view of its valuation can help you frame that decision. The share price recently closed at US$57.16, with a 17.6% gain over 30 days, a 16.7% return year to date, but a 40.4% decline over 1 year that sits alongside 57.7% and 58.6% declines over 3 and 5 years. These moves sit against a backdrop of ongoing interest in listed real estate and changing sentiment toward specialized...
NYSE:PCG
NYSE:PCGElectric Utilities

Is PG&E’s EMBERPOINT Wildfire-Mitigation Venture Altering The Investment Case For PG&E (PCG)?

Lockheed Martin, PG&E Corporation, Salesforce and Wells Fargo recently launched EMBERPOINT LLC, a joint venture that applies artificial intelligence, autonomous systems and integrated command-and-control tools to help first responders detect, prevent and combat catastrophic wildfires. A key feature of EMBERPOINT is that agencies and utilities can access advanced wildfire-mitigation technology without bearing development costs, potentially broadening adoption of these systems across...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

CorMedix (CRMD) Valuation Check After Recent Share Price Pullback And Melinta Acquisition Outlook

CorMedix overview and recent share performance CorMedix (CRMD) has drawn investor attention after a sharp pullback over the past month, with the share price down about 38% and roughly 30% lower over the past 3 months. That recent weakness comes despite a 1 day return of 6.74% and a 14.45% move over the past week. This may prompt some investors to reassess how the current price compares with the company’s fundamentals. See our latest analysis for CorMedix. Looking beyond the recent bounce,...
NasdaqGM:PEBK
NasdaqGM:PEBKBanks

Peoples Bancorp Of North Carolina (PEBK) Margin Gain And 21.3% Earnings Growth Reinforce Bullish Narratives

Peoples Bancorp of North Carolina (PEBK) just closed out FY 2025 with fourth quarter revenue of US$24.6 million and EPS of US$1.25, alongside trailing 12 month revenue of US$89.1 million and EPS of US$3.74 that reflects 21.3% earnings growth over the past year. Over recent periods, the company has seen quarterly revenue move from US$21.1 million in Q4 2024 to US$24.6 million in Q4 2025, while quarterly EPS shifted from US$0.67 to US$1.25. This sets up a story where improving margins and a...
NYSE:PMT
NYSE:PMTMortgage REITs

Is PennyMac Mortgage Investment Trust’s New Prime RMBS Deal Quietly Reframing Its Funding Strategy (PMT)?

KBRA recently assigned preliminary credit ratings to 56 classes of mortgage-backed notes from PMT Loan Trust 2026-CNF1, a prime RMBS transaction backed by 576 agency-eligible, conforming mortgage loans sponsored by PennyMac Corp., an indirect wholly owned subsidiary of PennyMac Mortgage Investment Trust. This fresh securitization highlights PennyMac Mortgage Investment Trust’s continued use of mortgage-backed markets to finance conforming, general QM loans and potentially broaden its...
NasdaqCM:USAU
NasdaqCM:USAUMetals and Mining

U.S. Gold (USAU) Is Up 9.8% After $31M CK Financing And Feasibility Progress - Has The Bull Case Changed?

U.S. Gold Corp recently advanced its CK Gold Project in Wyoming toward a Definitive Feasibility Study after securing US$31,000,000 in financing, while benefiting from record-high gold prices that enhance project economics and the perceived value of its Nevada and Idaho exploration assets. An interesting angle is how stronger gold prices can make mine-construction financing more attainable, potentially accelerating timelines for turning U.S.-based mineral resources into producing...
NasdaqGS:SRPT
NasdaqGS:SRPTBiotechs

Sarepta Therapeutics Elevidys Data Highlights Durable Duchenne Benefits And Risks

Sarepta Therapeutics (NasdaqGS:SRPT) reported positive 3 year data from the EMBARK Phase 3 study of Elevidys gene therapy in Duchenne muscular dystrophy. The results show sustained functional benefits in ambulatory Duchenne patients over 3 years with a manageable safety profile. No new safety issues were identified in the 3 year readout, addressing prior concerns around long term efficacy and safety. Sarepta Therapeutics focuses on genetic medicines for rare neuromuscular diseases, and...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

Is BridgeBio Pharma (BBIO) Still Attractively Priced After Strong Pipeline Progress And 7x Gain?

If you are wondering whether BridgeBio Pharma's share price still makes sense after a strong run, this article focuses on what the numbers say about value rather than the excitement around the stock. The stock trades at US$77.81, with returns of 2.0% over the past week, 2.7% over the past month, a slight year to date decline of 0.5%, a 112.2% return over the past year, a very large 3 year gain that is around 7x, and a 35.5% return over 5 years. Recent news around BridgeBio has centered on...
NYSE:PIPR
NYSE:PIPRCapital Markets

Is Piper Sandler (PIPR) Turning Efficiency Gains Into a More Durable Earnings Engine?

Piper Sandler Companies recently reported that over the past two years it has delivered strong annual growth in revenue, earnings per share, and tangible book value per share, all pointing to improved profitability and capital strength. What stands out is that earnings per share expansion has far outpaced revenue growth, implying meaningful efficiency gains and better operating leverage across the business. We’ll now examine how this outsized earnings growth, relative to revenue, may...
NYSE:CHWY
NYSE:CHWYSpecialty Retail

Chewy CTO Retirement Puts Technology Priorities And Valuation In Focus

Chewy (NYSE:CHWY) has announced the retirement of its Chief Technology Officer, Satish Mehta. The leadership transition affects oversight of Chewy's technology platforms and product development efforts. Stakeholders are assessing what this change could mean for the company's future technology priorities. Chewy, trading at $31.43, has seen its share price under pressure, with a 7 day return of a 6.8% decline and a 1 year return of a 19.3% decline. Over 3 years, the stock has recorded a 27.3%...
NYSE:DX
NYSE:DXMortgage REITs

Dynex Capital (DX) Dividend Strain Challenges Bullish Reaction To FY 2025 Earnings Rebound

Dynex Capital (DX) has wrapped up FY 2025 with Q4 total revenue of US$202.0 million and basic EPS of US$1.17, alongside trailing twelve month revenue of US$372.1 million and EPS of US$2.49. This sits next to a very large 190.8% earnings jump over the past year and an 11.4% annual earnings decline over five years. The company has seen quarterly revenue move from US$60.3 million in Q4 2024 to US$201.997 million in Q4 2025, while basic EPS shifted from US$0.61 to US$1.17 over the same period...
NasdaqCM:KARO
NasdaqCM:KAROSoftware

Is It Too Late To Consider Karooooo (KARO) After Its Strong Share Price Run?

After a strong run, you might be wondering whether Karooooo is still reasonably priced or starting to look stretched at current levels. The stock last closed at US$50.84, with returns of 8.6% over the past week, 7.3% over the last month, 13.8% year to date, and 19.6% over the past year. This puts recent price action front and center for anyone thinking about value. Over the past three years, Karooooo has delivered a total return of 122.8%, which gives useful context to the shorter term moves...
NYSE:DK
NYSE:DKOil and Gas

A Look At Delek US Holdings (DK) Valuation After Recent Share Price Weakness

Event context and recent price moves Delek US Holdings (DK) has been on investors’ radar after a recent pullback, with the stock down about 6% over the past month and about 26% in the past 3 months. See our latest analysis for Delek US Holdings. While the recent 30 day share price return of about 7% decline and 90 day share price return of about 26% decline suggest fading momentum, longer term total shareholder returns of 60% over one year and 72% over five years tell a different story. If...
NYSE:JBL
NYSE:JBLElectronic

Jabil Balances $1b Notes Offering With Advanced Semiconductor Expansion

Jabil (NYSE:JBL) announced a US$1b senior notes offering, aimed at reinforcing its capital structure. The company also revealed a new manufacturing collaboration with Eagle Harbor Technologies focused on advanced semiconductor fabrication. These updates highlight both a financing move and a shift toward deeper involvement in high-complexity semiconductor manufacturing. Jabil is known for contract manufacturing and supply chain services across electronics, healthcare, and other technology...
NasdaqGS:NAVN
NasdaqGS:NAVNHospitality

Navan Booking.com Expansion Tests Growth Story And Valuation Gap

Navan has expanded its partnership and direct API integration with Booking.com, broadening access to lodging options for corporate travelers. The upgrade gives Navan customers access to more properties, including in less conventional destinations, along with exclusive discounted rates. Travel managers gain stronger oversight tools, aimed at improving policy compliance and cost control across corporate travel programs. For investors watching NasdaqGS:NAVN, the Booking.com expansion comes as...
NasdaqGS:NTAP
NasdaqGS:NTAPTech

Assessing NetApp (NTAP) Valuation After Recent Share Price Weakness

Why NetApp Is On Investors’ Radar Today NetApp (NTAP) is back in focus after recent trading left the stock with a month return of about an 11% decline and a past 3 months return of roughly a 15% decline, inviting closer attention to its current valuation. See our latest analysis for NetApp. At around $98.81 per share, NetApp’s recent 7 day and 30 day share price returns of a 4.8% and 10.6% decline sit against a 1 year total shareholder return of a 15.9% decline. The 3 year and 5 year total...
OTCPK:PSBQ
OTCPK:PSBQBanks

PSB Holdings (OTCPK:PSBQ) Margin Improvement Reinforces Bullish Community Bank Narratives

PSB Holdings (PSBQ) closed out FY 2025 with fourth quarter revenue of US$13.5 million and EPS of US$0.97, rounding off a trailing twelve month run that produced revenue of US$51.4 million and EPS of US$3.32. Over the past year, revenue has moved from US$44.9 million to US$51.4 million and EPS has shifted from US$2.37 to US$3.32, setting up the current results against a period of rising profitability. With trailing net profit margin at 26.2% versus 21.9% a year earlier, the latest report...